The Filing Desk

Precision Biosciences

DTIL · Nasdaq · Health Care · Financials, fiscal 2018 to 2025

DTIL · Last close · November 19, 2026
$6.91
Value Precision Biosciences yourself

Precision Biosciences' revenue fell 50.1% to $34 million in fiscal 2025. Its operating margin was −152.2%, down from −38.1% a year earlier. Free cash flow was −$66 million. The diluted share count rose 86.3%.

PRECISION BIOSCIENCES INC Latest fiscal year ended December 31, 2025 10-K filed March 12, 2026 · 0001628280-26-017019 Updated
Revenue
$34M
50.1%
Operating margin
−152.2%
114.1 pts
Net income
−$46M
$7M a year earlier
Free cash flow
−$66M
 
Return on equity
−61.5%
80.6 pts
Market cap
$189M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (1-for-30.303), so every year is on today's share basis.

Charts show fiscal years, from the 10-K filings.

What Precision Biosciences does

Precision BioSciences is a clinical-stage gene editing company. It has developed a technology it calls ARCUS, a way to cut DNA at a chosen spot in order to insert, remove or cut out a piece of a gene inside the body. It has no approved products.

It is developing two gene editing therapies in clinical trials. PBGENE-HBV is aimed at chronic hepatitis B, a viral infection, by removing viral DNA. PBGENE-DMD is aimed at Duchenne muscular dystrophy, a muscle-wasting disease, by using two ARCUS enzymes delivered in one viral vehicle to cut out part of the defective dystrophin gene. The company says it is designed to potentially improve function for approximately 60% of patients with the disease.

The company formed in 2006. It signed a research and license agreement with Novartis in June 2022 for blood disorders such as sickle cell disease, and on October 31, 2025 it received written notice from Novartis that it was terminating that agreement.

Its biggest risks, as it describes them

  • It has lost money since it began and expects more losses.
  • It needs substantial additional funding, which could dilute owners or restrict it.
  • ARCUS is a new technology, so the time, cost and chance of success of its therapies are hard to predict.
  • Other gene editing technologies may prove better than ARCUS.
  • Its debt terms may limit what it can do.
From Precision Biosciences's annual report on Form 10-K, filed March 12, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Precision Biosciences lost money in fiscal 2025: a net loss of $46 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments14419011786116
Debt incl. finance leases222———
Net debt (negative means net cash)−141−167———
Net debt to EBITDA—————
Debt to equity0.0x0.4x———
Interest coverage−298.3x−56.1x−19.6x−14.7x−36.7x
Current ratio4.5x3.3x2.7x6.3x13.3x
Quick ratio4.5x3.3x2.7x6.3x13.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Precision Biosciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $63,215 of Precision Biosciences shares on the open market, and 4 insiders sold $412,359, all of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 28, 2026Stanley FrankelDirectorBought1,000$6.00$6,000Form 4
Sep 25, 2026Geno J GermanoDirectorBought2,609$6.28$16,385Form 4
Sep 25, 2026Melinda BrownDirectorBought1,135$6.27$7,116Form 4
Feb 18, 2026Michael AmorosoPresident and CEO, DirectorSold plan20,559$3.84$78,947Form 4
Feb 18, 2026John Alexander KellyChief Financial OfficerSold plan8,149$3.84$31,292Form 4
Feb 18, 2026Smith J. JeffersonChief Research OfficerSold plan4,925$3.84$18,912Form 4
Jan 22, 2026Michael AmorosoPresident and CEO, DirectorSold plan34,799$4.17$145,112Form 4
Jan 21, 2026John Alexander KellyChief Financial OfficerSold plan15,213$4.03$61,308Form 4
Jan 21, 2026Smith J. JeffersonChief Research OfficerSold plan10,200$4.03$41,106Form 4
Jan 21, 2026Dario ScimecaGeneral Counsel and SecretarySold plan8,854$4.03$35,682Form 4
Dec 16, 2025Geno J GermanoDirectorBought3,000$4.72$14,160Form 4
Dec 16, 2025Stanley FrankelDirectorBought2,700$4.70$12,690Form 4
The latest 12 of 13 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−82.5%−44.5%−242.5%
Altman Z''−8.14−8.23−7.20
Accruals ratio11.5%44.3%13.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailPassFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassFail
Cash from operations exceeds net incomeFailFailFail
Debt fell relative to assets———
Current ratio roseFailPassPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassPassFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Precision Biosciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Precision BiosciencesFY25−50.1%−152.2%−192.4%———
C4 TherapeuticsFY251.0%−320.5%−276.2%——3Compare
Kymera TherapeuticsFY25−16.7%−891.1%−597.6%———Compare
Voyager TherapeuticsFY25−49.5%−326.6%−334.5%———Compare
Editas MedicineFY2525.4%−394.9%−409.3%——2Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

8 years of figures

Fiscal yearFY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue111,0702411625496934
Revenue growth—9,731.9%−97.7%375.7%−78.3%94.2%41.0%−50.1%
Gross profit————————
Research and development45829811546536054
Operating income−48−87−110−39−62−44−26−52
Net income−46−93−109−31−112−617−46
Diluted EPS (US$)−87.60−66.30−62.70−15.60−38.10−15.961.04−3.56
Diluted shares (millions)012234713
Cash flow
Cash from operations−52−71−87−11−46−84−58−66
Capital expenditure1425553200
Free cash flow−66−96−92−16−49−86−59−66
Dividends paid00000000
Share buybacks00000000
Acquisitions00000000
Stock-based compensation29141619141310
Balance sheet at fiscal year end
Cash and short-term investments1031819014419011786116
Debt incl. finance leases———222———
Total assets139235150212238160136154
Total liabilities99971061201781418062
Shareholders' equity40138449160195692
Margins and ratios
Gross margin————————
Operating margin−440.2%−8.2%−452.2%−34.1%−248.3%−89.8%−38.1%−152.2%
Net margin−423.0%−8.7%−448.9%−26.5%−444.8%−125.8%10.4%−133.4%
Free cash flow margin−606.5%−8.9%−380.6%−13.8%−195.5%−176.6%−85.4%−192.4%
Rule of 40 (growth + FCF margin)—9,722.9%−478.3%361.9%−273.8%−82.5%−44.5%−242.5%
Return on capital————————
Return on equity—−104.2%−119.3%−45.1%−147.3%−154.7%19.1%−61.5%
Return on assets—−49.7%−56.6%−16.9%−49.6%−30.8%4.8%−31.4%
Net debt to EBITDA————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Precision Biosciences' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Precision Biosciences.